Clinical Trials
Making Clinical Trials Better for Everyone in 2023
Getting clinical trials to the finish line is not easy. Between 15% to 40% ...
Two Key Questions About Clinical Trials in 2023
PM360 asked experts in clinical trials about the evolution of decentralized research and what ...
What Does It Take to Design a Patient-centric Clinical Trial Protocol?
Clinical trial protocol writing teams usually start with scientific objectives, and ideally with the ...
Evolution of ePROM: Advancements, Concerns, and the Way Forward
Patients’ directly reported outcomes in certain rare and chronic diseases are considered reliable for ...
Digital Thread Solutions Can Speed Scale-up and Shorten Time to Market for Pharma
In the pharmaceutical business, as with any other business, you can’t market what you ...
Set Your Trial Up for Success—Select Your CRO and Decentralized Vendors in Parallel
Selecting the right Contract Research Organization (CRO) for your clinical trial is a common ...
New Developments in Gynecological Cancer Research
Substantial unmet needs exist in the diagnosis and treatment of gynecologic cancers. Often, these ...
Deploying AI for Greater Efficiency in Clinical Trial Recruitment
Clinical trial recruitment is a lengthy and complex process involving stringent protocols and the ...
Digital Therapeutics Companies Lean into Decentralized Clinical Trials
While digital therapeutics (DTx) companies are extremely optimistic about the promise of software-based interventions ...
PM360 Q&A with Victoria Donovan, Founder and CEO, Clinically Media
As with many other areas of healthcare, COVID-19 has accelerated the transformation of clinical ...
Enhancing Patient Access and Retention in Rare Disease Clinical Trials
Rare diseases were in the spotlight recently when an early-stage clinical trial involving gene-editing ...
The Future of Clinical Trials is Here Today
The healthcare industry’s traditional model for medical research long has been costly, slow, and ...
Digital Transformation in Drug Development and Innovating for Durable Competitive Advantage
The biopharmaceutical industry was already adapting to enormous change before COVID hit but, as ...
